Beam Therapeutics Inc. Quarterly Operating Income (Loss) in USD from Q1 2019 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Beam Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q3 2024.
Beam Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$107M, a 1.63% increase year-over-year.
Beam Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$183M, a 54.1% increase year-over-year.
Beam Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$176M, a 47.9% increase from 2022.
Beam Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$338M, a 13.8% increase from 2021.
Beam Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$392M, a 196% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$183M	-$107M	+$1.76M	+1.63%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-05
Q2 2024	-$184M	-$105M	-$2.75M	-2.69%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-06
Q1 2024	-$182M	-$104M	-$5.2M	-5.26%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$176M	$133M	+$222M		Oct 1, 2023	Dec 31, 2023	10-K	2024-02-27
Q3 2023	-$398M	-$108M	-$17M	-18.6%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-05
Q2 2023	-$381M	-$102M	-$20.2M	-24.6%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-06
Q1 2023	-$361M	-$98.9M	-$22.7M	-29.8%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$338M	-$89M	-$25.5M	-40.2%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-27
Q3 2022	-$313M	-$91.3M	-$21.7M	-31.1%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-08
Q2 2022	-$291M	-$82M	-$23M	-39%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-08
Q1 2022	-$268M	-$76.2M	+$124M	+62%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-10
Q4 2021	-$392M	-$63.5M	-$22.7M	-55.6%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-27
Q3 2021	-$370M	-$69.6M	-$32.3M	-86.6%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-07
Q2 2021	-$337M	-$59M	-$32.7M	-124%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$305M	-$200M	-$172M	-607%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-09
Q4 2020	-$133M	-$40.8M	-$14.4M	-54.7%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-28
Q3 2020	-$118M	-$37.3M	-$19.3M	-107%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-08
Q2 2020	-$99M	-$26.3M	-$8.63M	-48.9%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-10
Q1 2020	-$90.4M	-$28.4M	-$15.2M	-116%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q4 2019	-$75.2M	-$26.4M			Oct 1, 2019	Dec 31, 2019	10-K	2022-02-28
Q3 2019		-$18M			Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-10
Q2 2019		-$17.7M			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-12
Q1 2019		-$13.1M			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12

* An asterisk sign (*) next to the value indicates that the value is likely invalid.